Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Olema Pharmaceuticals Inc (OLMA)
Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

ONCY : 0.9920 (-4.15%)
ONC.TO : 1.34 (-4.29%)
PFE : 27.84 (+1.05%)
ARVN : 47.31 (+1.72%)
OLMA : 13.57 (+0.67%)
AZN : 65.84 (+2.67%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

AVRN : 0.0125 (-30.56%)
ONCY : 0.9920 (-4.15%)
ONC.TO : 1.34 (-4.29%)
PFE : 27.84 (+1.05%)
ARVN : 47.31 (+1.72%)
OLMA : 13.57 (+0.67%)
AZN : 65.84 (+2.67%)
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancerReported progress across OP-1250 clinical...

OLMA : 13.57 (+0.67%)
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement...

OLMA : 13.57 (+0.67%)
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage...

OLMA : 13.57 (+0.67%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage...

OLMA : 13.57 (+0.67%)
Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

NVS : 103.98 (+1.15%)
PFE : 27.84 (+1.05%)
BEAM : 34.59 (+3.13%)
OLMA : 13.57 (+0.67%)
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer

SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S....

OLMA : 13.57 (+0.67%)
2 “Strong Buy” Penny Stocks That Could See Huge Long-Term Gains

The first half of 2022 was marked by concerns over inflation, rising interest rates and recession, with the S&P 500 registering its worst half year since 1970. However, not everyone is seeing dark times...

CDAK : 0.0570 (-55.98%)
OLMA : 13.57 (+0.67%)
Olema Pharmaceuticals (OLMA) Gets a Buy Rating from Cowen & Co.

In a report released yesterday, William Maughan from Cowen & Co. reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report), with a price target of $16.00. The company's shares closed...

OLMA : 13.57 (+0.67%)

Barchart Exclusives

3 Unusually Active Options to Consider for the Long Haul
Thursday’s unusual options activity included 36 puts and calls expiring over 365 days. That’s a decent amount. While tempting, I’m looking for options with a slightly shorter duration. Here are my three to consider for the long haul. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar